Palatal tremor in relation to brainstem tumour involvement

Joana Marques,1 Hipólito Nzwalo,2 Ana Azevedo,1 Duarte Salgado1

DESCRIPTION
A 32-year-old woman with idiopathic congenital moderate mental retardation was being followed because of presumed primary central nervous system lymphoma (previous clinical evolution and investigation summarised in table 1)

She was admitted for clinical re-evaluation because of motor and cognitive deterioration. She was bedridden, tetraparetic, with severe cognitive impairment preventing any verbal communication, apart from elementary responses. During the first week of hospitalisation she developed persistent elementary vocal tics and swallowing disturbance, often showing facial signs of discomfort. Oropharyngeal examination revealed the presence of continuous rhythmic movement of the soft palate typical of palatal tremor (video 1) which was also present during sleep. No repetitive audible clicks were noticed. Brain magnetic resonance disclosed the presence of lesions involving the dorsal midbrain tegmentum and periaqueductal area without hypertrophy of the inferior olive (figures 1 and 2).

Baclofen was introduced with slight symptomatic relief. Palatal tremor, also called palatal myoclonus, is a rare movement disorder characterised by brief, rhythmic involuntary movements of the soft palate. It is presumably caused by dysfunction (essential palatal tremor) or a lesion (symptomatic palatal tremor), involving the Guillain-Mollaret triangle also known as ‘myoclonic triangle’ (dentate nucleus, red nucleus, inferior olivary nucleus and central tegmental tract). Brainstem or cerebellar disorders such as stroke, demyelinating diseases,

To cite: Marques J, Nzwalo H, Azevedo A, et al. BMJ Case Rep Published online: [please include Day Month Year] doi:10.1136/bcr-2013-009438

Table 1 Previous clinical evolution and investigation

<table>
<thead>
<tr>
<th>Year</th>
<th>Clinical and imagiological findings</th>
<th>Investigation</th>
<th>Treatment/evolution</th>
<th>Presumed diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>2000</td>
<td>Somnolence, progressive right-sided hemiparesis brain magnetic resonance: left-sided hypointense on T2-weighted with homogeneous gaddolinium-enhancing lenticulo-thalamo-capsular lesion (tumour? inflammatory?)</td>
<td>Negative extensive blood* and CSF** testing; normal EEG; biopsy postponed : deep location of the lesions, disappearance with corticotherapy</td>
<td>Corticotherapy/ clinical and radiological remission</td>
<td>Primary CNS*** vasculitis?</td>
</tr>
<tr>
<td>2000 (3 weeks later)</td>
<td>Right-sided central facial paresis, spastic paretic gait resurgence of prior lesion brain magnetic resonance</td>
<td>Negative extensive blood and CSF testing; normal EEG; HLA typing: A24; B07, DRB1 11:04, 11:07; DQB1 03:01, 03:03</td>
<td>Corticotherapy/ partial clinical and radiological remission</td>
<td>Primary CNS vasculitis?</td>
</tr>
<tr>
<td>2011</td>
<td>Headache, confusional state, residual right crural paresis brain magnetic resonance: multiple nodular hypointense on T2-weighted with homogeneous T1 gadolinium-enhancing supratentorial lesions</td>
<td>Inconclusive biopsy (encephalitis? lymphoma?): presence of reactive astrocytes and microglosis, perivascular mononuclear infiltrates; atypical T and B lymphocytes on immunohistochemical staining—— negative extensive blood and CSF investigation; normal EEG</td>
<td>Corticotherapy/ clinical and radiological remission</td>
<td>Primary CNS lymphoma?</td>
</tr>
<tr>
<td>2013</td>
<td>Tetraparesis, worsening of the pre-existing cognitive impairment brain magnetic resonance: hypointense on T2-weighted a with T1 gadolinium-enhancing lesions in the dorsal midbrain tegmentum and periaqueductal area</td>
<td>Negative extensive blood and CSF testing; normal EEG</td>
<td>Corticotherapy</td>
<td>Primary CNS lymphoma?</td>
</tr>
</tbody>
</table>

*antineutrophilic cytoplasmic antibodies, antinuclear antibody, antiphospholipid antibodies, C-reactive protein, haemosedimentation rate, renal function, hepatic function, electrolytes, lactate, pyrovan, aspartate A, thyroid function, adrenal function, HIV, hepatitis B and C virus.

**neutrophic virus, John Cunningham virus, immunophenotyping.

***Central nervous system.

CSF: cerebrospinal fluid; CNS, central nervous system; HLA, human leucocyte antigen.
trauma and tumours are often identified. There is no established treatment for palatal tremor. Palatal botulinum toxin injections, and other drugs such as clonazepam, flunarizine, baclofen or sumatriptan are used, but these interventions are often unsuccessful.

Learning points

▸ Palatal tremor is a rare movement disorder; when symptomatic (secondary) is usually described in association with lesions involving the Guillain-Mollaret triangle.
▸ Brain magnetic resonance is mandatory to identify an underlying lesion, particularly in cases of central nervous system tumours.

Contributors HN designed the study. JM wrote the manuscript; AA collected the data and drafted the manuscript; DS wrote and revised the manuscript. All authors read and approved the final manuscript.

Competing interests None.

Patient consent Obtained.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

2 Penney SE, Bruce IA, Saeed SR. Botulinum toxin is effective and safe for palatal tremor: a report of five cases and a review of the literature. J Neurol 2006;253:857–60.